Nils Erik, G. & Jan, V. J. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. (2015). This important article discusses the classification subgroups of myasthenia gravis and the various therapeutic strategies that can be employed to manage the condition effectively.
Rui, Z., Sushan, L. & Chongbo, Z. The role of innate immunity in myasthenia gravis. Autoimmun. Rev. (2021).
James, F. H. Jr. et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. (2020). This landmark trial highlights the promising therapeutic potential of zilucoplan, offering a new treatment paradigm for individuals battling this debilitating condition.
Donald, B. S. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology (2016). This executive summary provides foundational guidance for clinicians managing myasthenia gravis, aiming to standardize treatment approaches globally.
Thomas, C. E. et al. Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology (1997). This study highlights the various clinical features and complexities associated with myasthenic crises, emphasizing risk factors for prolonged intubation.
James, F. H. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. (2021). This pivotal phase 3 trial assessed the safety and efficacy of efgartigimod, paving the way for future therapeutic options in managing generalized myasthenia gravis.
What are the key management strategies recommended in the international consensus guidance for myasthenia gravis?
The text you provided contains references from a scientific article related to myasthenia gravis. Here’s a brief overview of the key references mentioned in the excerpt:
1. **James, F. H. Jr. et al.** “Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.” *JAMA Neurol.* (2020). DOI: [10.1001/jamaneurol.2019.5125](http://scholar.google.com/scholar_lookup?&title=Clinical%20effects%20of%20the%20self-administered%20subcutaneous%20complement%20inhibitor%20zilucoplan%20in%20patients%20with%20moderate%20to%20severe%20generalized%20myasthenia%20gravis%3A%20Results%20of%20a%20phase%202%20randomized%2C%20double-blind%2C%20placebo-controlled%2C%20multicenter%20clinical%20trial&journal=JAMA%20Neurol.&doi=10.1001%2Fjamaneurol.2019.5125&publication_year=2020&author=James%2CFH).
2. **Donald, B. S. et al.** “International consensus guidance for management of myasthenia gravis: Executive summary.” *Neurology* (2016). This reference discusses a standardized approach to management of myasthenia gravis. DOI: [10.1212/wnl.0000000000002790](https://doi.org/10.1212%2Fwnl.0000000000002790).
3. **Thomas, C. E. et al.** “Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation.” *Neurology* (1997). This study reviews the complexities of myasthenic crises, emphasizing factors associated with prolonged intubation. DOI: [10.1212/wnl.48.5.1253](https://doi.org/10.1212%2Fwnl.48.5.1253).
4. **James, F. H. Jr. et al.** “Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial.” *Lancet Neurol.* (2021). This trial evaluated the safety and efficacy of efgartigimod in treating generalized myasthenia gravis.
This information could assist in further understanding treatments and management strategies for myasthenia gravis. If you need more specific details or summaries on any of these articles, please let me know!
